DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Sartore-Bianchi A. et al.
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Lancet Oncol 2016;
17: 738-746
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.